Panbela Therapeutics, Inc. has filed a Prospectus Supplement No. 2 to its existing prospectus dated December 20, 2023, with the SEC on July 30, 2024. This supplement includes information from the company's recent Form 8-K filing, which details a new Loan Agreement with USWM, LLC. Under this agreement, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have secured a term loan of $1.5 million. The loan, which matures on the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024, carries an interest and premium of $375,000, plus an additional 10% of proceeds from a Qualifying Transaction, capped at $1 million. The company has also committed to using commercially reasonable efforts to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. The...Show More

Panbela Therapeutics, Inc. has filed a Prospectus Supplement No. 2 to its existing prospectus dated December 20, 2023, with the SEC on July 30, 2024. This supplement includes information from the company's recent Form 8-K filing, which details a new Loan Agreement with USWM, LLC. Under this agreement, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have secured a term loan of $1.5 million. The loan, which matures on the earlier of a Qualifying Financing, a Qualifying Transaction, or December 31, 2024, carries an interest and premium of $375,000, plus an additional 10% of proceeds from a Qualifying Transaction, capped at $1 million. The company has also committed to using commercially reasonable efforts to complete a Qualifying Financing by the end of 2024 and a Qualifying Transaction by July 24, 2025. The loan proceeds are designated for specific uses, including payment to a contract research organization, working capital purposes, and related fees or expenses. Additionally, the loan is secured by a first priority interest in all rights, title, and interest in the Asset Purchase Agreement between the company and the lender. The Prospectus Supplement No. 2 also informs investors of the risks associated with investing in Panbela Therapeutics' securities and updates the resale information of up to 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA,' with the last reported sales price being $0.35 per share as of July 29, 2024.